Events & Training for October 2017

ELRIG Drug Discovery 2017

03 October 2017 - 04 October 2017

Drug Discovery is ELRIG’s flagship event. Now in its 11th year, we return to ACC in Liverpool to bring together the leading lights in drug discovery research across pharma, biotech, academia and the vendor community. The meeting will feature over 50 world-class speakers in 6 main session tracks, each highlighting the latest scientific breakthroughs and new approaches that are driving this success. This conference will explore innovative technologies and approaches that can be used to overcome drug development challenges, and bring together industry leaders who will discuss future opportunities for novel therapeutic discovery. Scientific tracks will cover: Innovations in Chemistry Target Identification and Validation Innovations in Assay Design, Development and Screening Advances in Imaging Drug Discovery in the 4th Dimension From Molecule to Man: Right dose, first time There will also be a series of vendor workshops, which will provide a more informal, interactive environment for you to discuss key issues and future directions in workshops coordinated by leaders in the fields. Drug Discovery 2017 will include a high quality scientific poster session, networking opportunities, and an extensive vendor exhibition featuring around 100 companies. And don’t miss the Innovation Zone, for new and exciting emerging companies and technologies.

ACC, Liverpool, UK

Festival of Genomics Boston

03 October 2017 - 04 October 2017

Our Flagship event returns to Boston on the 3rd – 4th October 2017. The Festival provides a unique opportunity to meet with the whole of the genomics community, in an environment carefully constructed to facilitated networking, learning and business growth. Across the two days, four core themes will be addressed by high profile speakers from respected organizations. Listen, discuss and get in on the debates about Personalizing Medicine, Precision Therapeutics, Enabling Data and Research & Development. We know knowledge is power and different experiences can help you learn and retain information. Therefore we have 5 stages oozing with sessions of all different shapes, sizes and formats. Check out all of them to get the full 360 experience of the Festival. Some exciting features for 2017 include: Live Lounge, Talkaoke, Poster Zone, Game of Genomes Panel, Buyer's Concierge, Disorder Rare Disease Short Film Festival and so much more… Use discount code FOG77 when registering online at to get your FREE Festival pass!

Boston Convention and Exhibition Center, Boston, Massachusetts, USA

Pharmaceutical Pricing and Market Access 2017

11 October 2017 - 12 October 2017

SMi Group is proud to present the 23rd annual industry leading summit on Pharmaceutical Pricing & Market Access, taking place on 11th & 12th October 2017 in Central London. Mounting criticism from a surge in the price of drugs has added growing pressure on pharmaceutical companies and manufactures to limit future price increases and on payers to be more cost-effective in their approach to setting budgets and managing costs. Drawing from over two decades worth of expertise, Pharmaceutical Pricing & Market Access 2017 will address these challenges head on by preparing attendees to develop a successful market access strategy for the ever-changing payer landscape. Join us this autumn for exclusive case study insight into how manufactures plan to limit further price increase; a progressive outlook into the future of pharmaceutical pricing & reimbursement (P&R); and discuss what can be done by all stakeholders for the industry to achieve efficient reimbursement and for patients to gain access to affordable medication. Featured speakers include: • Barbara Jaszewski, VP Global Pricing and Market Access, Lundbeck (Conference chair) • Nneka Onwudiwe, PRO/PE Regulatory Review Officer, FDA • Patrick Mollon, Director Health-Economics, Outcomes Research & Epidemiology, Shire • Fabrizio Zucca, Director Patient Access, Sobi • Klaas Postema, Sr Director Market Access & Pricing Generics Europe, Teva • Mercedes Prior, International Market Access Director, Grifols • Anne Marciniak, Senior Director, International HEOR, Allergan • Ritva Lehtonen, Market Access & External Affairs Director, Sanofi Reasons to Join: • Increase compliance and navigate the regulatory landscape through informed guidance presented by the FDA in an opening keynote address • Develop strategies for market access and expansion by; defining your target audience; identifying key economic advantages; and generating appropriate clinical and health economic evidence to support a strong value proposition • Utilise strategic partnerships by learning best practice in collaborating with payers, data providers and health stakeholders • Drive commercial competitiveness by uncovering new windows of opportunity in growing markets such as orphan drugs, biosimilars and gene therapy • Make informed decisions from development through to reimbursement by optimising meaningful patient engagement opportunities • Explore ways in which the HTA and Regulatory Agencies can work together to meet patient needs • Strengthen your strategic capabilities by hearing the latest updates through a selection of global case studies on translational market access, international reference pricing and value based pricing • Secure commercial viability by discovering new market access algorithms for innovative drugs • Showcase product value by implementing real world data into pricing and utilising Real World Evidence (RWE) for payer decision making

Holiday Inn Kensington Forum, London, UK

7th Annual Orphan Drugs and Rare Diseases UK

18 October 2017 - 19 October 2017

SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th & 19th October 2017 in Central London, UK. This year’s theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research. Aimed at an audience of senior scientists and oncology specialists involved in targeting rare diseases therapies and drug research, Orphan Drugs UK 2017 will provide a perfect platform to discuss pioneering clinical developments and the next generation of clinical trial process. The 7th annual conference will capture expert insight through dedicated focus new therapies for different rare diseases, the importance of orphan drug development and reimbursement and repurposing. Join us this October for strategic direction from the Rare Disease community and leverage your knowledge with the key requirements and tools for successful patient recruitment and retention through informed guidance delivered by a panel of industry experts.

Holiday Inn Kensington Forum, London, UK

Novel Cancer Therapeutics Summit 2017

19 October 2017 - 20 October 2017

We invite you to attend the 2017 Novel Cancer Therapeutics Summit, to be held on October 19-20, 2017 in San Diego, CA. This summit includes three parallel conferences focused on both the research, and business perspectives in oncology. This summit will continue to be a premier event for translational researchers, preclinical scientists and managers, and those carrying out early phase clinical trials working to identify and exploit advances in the field of oncology in order to deliver products with a meaningful clinical impact. In addition, industry leaders from big pharma and various biotech/pharmaceutical companies, including business/corporate development executives, licensing executives, global alliance, and venture capitalists, will all be present to explore potential collaborations and learn about relevant issues in oncology. Focus areas include cancer diagnostics, cancer immunotherapy, as well as partnering and deal-making in oncology. Discussion topics include emerging targets, therapeutic strategies, next generation sequencing in cancer diagnosis, progress in cancer immunotherapy, combination strategies in immuno-oncology, advancements in technology, as well as business development trends, markets, partnership opportunities, and access to capital market. Both cutting-edge researchers and those who guide its commercial development will be on-hand to share their knowledge and insights as to how therapeutic cancer targets are identified, and how this research translates into meaningful therapeutics that benefit patients living with cancer!

San Diego, CA, USA tbc